Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of...
Reexamination Certificate
2004-03-03
2010-02-23
Woitach, Joseph (Department: 1633)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
C536S024100
Reexamination Certificate
active
07666670
ABSTRACT:
In a first aspect the present invention provides a tumor cell line stably transfected with an expression vector containing a reporter gene, preferably a fluorescent protein, operably linked to a promotor that also controls expression of a protein that is associated with tumor regression, stabilization of tumor growth or inhibition of metastatic growth, characterized in that said cell line is capable to form a tumor when implanted or injected into the non-human animal. Compared to the traditional in vivo models, the present invention differs in that the reporter gene is not constitutively expressed, but only after exposure to a test compound that results in the expression of a protein or enzyme associated with tumor regression, stabilization of tumor growth or inhibition of metastatic growth. Only when a compound to be tested got into circulation and infiltrated the tumor it may generate the reporter signal, provided it promotes the expression of a protein associated with tumor regression and the promoter of said protein is operably linked to the reporter gene.
REFERENCES:
patent: 2002/0197676 (2002-12-01), Lukyanov et al.
patent: 2003/0228627 (2003-12-01), Emerson et al.
patent: 94/16080 (1994-07-01), None
patent: 97/18841 (1997-05-01), None
patent: 02/055742 (2002-07-01), None
Zitvogel et al, Human Gene Therapy 5(12): 1493-1506, 1994. Abstract only.
Kuo et al, Exp. Cell. Res Exp. Cell Res. (2007), doi:10.1016/j.yexcr.2007.02.010.
Tang et al, J. Biol. Chem 273(44): 29156-29163, 1998.
Sowa et al, Ann. N. Y. Acad. Sci. 886: 195-199, 1999.
Margueron et al, J. Mol. Endocrinol. 32: 583-594, 2004.
Elbendary et al, Cell Growth and Differentiation 5: 1301-1307, 1994.
Nie et al., “A facile and effective screening method for p21WAF1 promoter activators from microbial metabolites”, The Journal of Antibiotics, vol. 54, No. 10, pp. 783-788 (2001).
Shinagawa et al., “Evaluation of the chemosensitivity of head and neck cancer cells based on the diverse function of mutated-p53”, International Journal of Oncology, vol. 22, No. 2, pp. 383-389 (2003).
Park et al., “P53 Transactivation through various p53-responsive elements”, Molecular Carcinogenesis, vol. 16, No. 2, pp. 101-108 (1996).
Wang et al., “HIPK2 overexpression leads to stabilization of p53 protein and increased p53 transcriptional activity by decreasing Mdm2 protein levels”, BMC Molecular Biology, vol. 2, No. 8, pp. 1-9 (2001).
Doubrovin et al., “Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo”, Proceedings of the National Academy of Sciences of the United States of America, vol. 98, No. 16, pp. 9300-9305 (2001).
Khanna et al., “Cyclosporine induces the expression of the cyclin inhibitor p21”, Transplantation, vol. 67, No. 9, pp. 1262-1268 (1999).
International Search Report dated Jul. 5, 2004 for related International Application No. PCT/EP2004/002195.
Arts Janine
Beliën Ann Trudo Josée
Mariën Ann Odette Adolf
Valckx Annemie Francine
Hill Kevin K.
Janssen Pharmaceutica N.V.
Woitach Joseph
LandOfFree
Animal model for the fast identification of pharmaceutical... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Animal model for the fast identification of pharmaceutical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Animal model for the fast identification of pharmaceutical... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4218921